범불안장애(GAD) 시장 : 인사이트, 역학 및 시장 예측(2032년)

Generalized Anxiety Disorder Market Insight, Epidemiology And Market Forecast - 2032

US $ 7,500 ￦ 10,431,000

PDF (Single User License)

PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 11,250 ￦ 15,646,000

PDF (2-3 User License)

PDF 보고서를 동일 사업장에서 3명까지 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 15,000 ￦ 20,862,000

PDF (Site License)

PDF 보고서를 동일 사업장의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 22,500 ￦ 31,293,000

PDF (Global License)

PDF 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

한글목차

주요 하이라이트

• 범불안장애(GAD) 시장은 예측 기간(2023-2032년) 동안 안정적인 성장을 보일 것으로 예상됩니다. 7대 주요 불안장애(GAD) 시장 시장 규모는 더 나은 진단과 새로운 치료제의 출시로 인해 확대될 것으로 예상됩니다.
• 7개 주요 시장에서 진단된 범불안장애(GAD) 환자 중 약 53%가 미국에 있는 것으로 추정됩니다. 당사의 추정에 따르면, 2022년 유럽 4개국 및 영국이 GAD 환자 중 약 600만 7,995명을 차지했습니다.
• 7대 시장에서는 SSRI/SNRI, 벤조디아제핀, 삼환계 항우울제/아자피론(부스피론), 기타(항경련제, 항정신병 약물 등) 표준 치료제로 구성된 시장이 2022년 약 15억 달러 시장을 형성했습니다.
• 범불안장애(GAD) 치료제 시장 규모는 MM-120(LSD D-tartrate), Fasedienol(PH94B)과 같은 새로운 효과적인 치료제의 등장으로 예측 기간 동안 성장할 것으로 예상됩니다.

전반적인 불안장애(GAD) 시장 전망

Fasedienol 및 MM-120과 같은 잠재적 약물의 승인으로 인해 시장은 긍정적인 성장을 보일 것으로 예상됩니다.

• 범불안장애(GAD)의 7개 주요 시장의 총 시장 규모는 2022년 약 15억 달러에 달했습니다. 예측 기간 동안 상당한 성장이 예상됩니다.
• 주요 7개 시장 중 미국이 2022년 약 64%로 가장 큰 점유율을 차지하며 시장을 독점했습니다.
• 2022년 유럽 4개국 및 영국이 4억 4,300만 달러로 추정되며, 상당한 CAGR을 기록할 것으로 예상됩니다. 유럽 국가 중 독일이 2022년 가장 큰 시장 점유율을 차지했으며, 이탈리아, 스페인이 그 뒤를 이었습니다.
• 일본은 2022년 전체 범불안장애(GAD) 시장의 약 7%를 차지했으며, 조사 기간 동안 상당한 CAGR로 증가할 것으로 예상됩니다.
• 범불안장애(GAD) 치료 시장의 총 시장 규모는 새로운 효과적인 치료법의 등장으로 예측 기간 동안 성장할 것으로 예상됩니다.

본 보고서는 미국, 독일, 스페인, 이탈리아, 프랑스, 영국, 일본 등 주요 7개국(미국, 독일, 스페인, 이탈리아, 프랑스, 영국, 일본)의 주요 불안장애(GAD) 시장을 조사 분석하여 각 지역 시장 규모, 현재 치료법, 미충족 수요, 신약 등에 대한 정보를 제공합니다.

목차

제1장 프리미엄 인사이트

제2장 보고서 서론

제3장 범불안장애(GAD) 시장 개요

• GAD 시장 점유율 분포 : 치료법별(2019년)
• GAD 시장 점유율 분포 : 치료법별(2032년)

제4장 GAD 역학과 시장 조사 방법

제5장 범불안장애(GAD) 주요 요약

제6장 주요 이벤트

제7장 질환의 배경과 개요

• 서론
• 원인과 위험 요인
• 징후와 증상
• 병태생리학
• 진단
• 범불안장애 치료와 관리

제8장 역학과 환자수

• 주요 조사 결과
• GAD 전제조건과 근거
  • 미국
  • 유럽 4개국/영국
  • 일본
• 주요 7개 시장에서 진단된 GAD 총환자수
• 미국
• 유럽 4개국/영국
  • 독일
  • 프랑스
  • 이탈리아
  • 스페인
  • 영국
• 일본

제9장 GAD 환자 여정

제10장 새로운 치료법

• 주요 경쟁
• Fasedienol(PH94B) : VistaGen Therapeutics
• MM-120: MindMed
• SEP-363856(Ulotaront) : Sumitomo Pharma America, Inc./Otsuka Pharmaceutical Co., Ltd/Sunovion Pharmaceuticals Inc.
• CYB004: Cybin IRL Limited
• ENX-102: Engrail Therapeutics INC
• BNC210: Bionomics Limited
• RLS103: Receptor Life Sciences/MannKind Corporation

제11장 GAD : 시장 분석

• 주요 조사 결과
• 주요 시장 예측의 전제조건
• 시장 전망
• 주요 7개 GAD 전체 시장 규모
• 주요 7개 GAD 시장 규모 : 치료법별
• 미국의 GAD 시장 규모
  • GAD 전체 시장 규모
  • 미국의 GAD 시장 규모 : 치료법별
• 유럽 4개국/영국의 GAD 시장 규모
  • 독일
  • 프랑스
  • 이탈리아
  • 스페인
  • 영국
• 일본의 GAD 시장 규모
  • 일본의 GAD 시장 규모 : 치료법별

제12장 KOL(Key Opinion Leader)의 견해

제13장 SWOT 분석

제14장 미충족 요구

제15장 시장 참여와 상환

• 미국
• 유럽 4개국/영국
  • 독일
  • 프랑스
  • 이탈리아
  • 스페인
  • 영국
• 일본

제16장 부록

제17장 DelveInsight의 서비스 내용

제18장 면책사항

LSH

영문 목차

영문목차

Key Highlights:

• The Generalized Anxiety Disorder (GAD) market is projected to witness consistent growth throughout the forecast period (2023-2032). The market size of Generalized Anxiety Disorder (GAD) in the 7MM is expected to increase, driven by better diagnosis and the launch of emerging therapies.
• DelveInsight's analyst projects that among the total diagnosed prevalent cases of Generalized Anxiety Disorder (GAD) in 7MM approximately 53% of cases were from the US. As per our estimations, in 2022, the EU4 and the UK accounted for nearly 6,007,995 diagnosed prevalent cases of GAD.
• In the 7MM, the market mainly consisted of standard treatments like SSRIs/SNRIs, Benzodiazepines, Tricyclic Antidepressants/Azapirone (Buspirone), and others (Antiepileptics, antipsychotics, etc.) which generated nearly USD 1,500 million in 2022.
• The total market size of the Generalized Anxiety Disorder (GAD) treatment market is anticipated to experience growth during the forecast period due to the emergence of new and effective treatments, namely, MM-120 (LSD D-Tartrate), Fasedienol (PH94B), and others.

DelveInsight's "Generalized Anxiety Disorder (GAD) - Market Insights, Epidemiology, and Market Forecast - 2032" report delivers an in-depth understanding of the Generalized Anxiety Disorder (GAD), historical and forecasted epidemiology and the Generalized Anxiety Disorder (GAD) market trends in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan.

The Generalized Anxiety Disorder (GAD) market report provides current treatment practices, emerging drugs, market share of individual therapies, and current and forecasted 7MM Generalized Anxiety Disorder (GAD) market size from 2019 to 2032. The report also covers current Generalized Anxiety Disorder (GAD) treatment practices/algorithms and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the market.

Geography Covered:

• The United States
• EU4 (Germany, France, Italy, and Spain) and the United Kingdom
• Japan

Study Period: 2019-2032.

Disease Understanding and Treatment Algorithm

Generalized Anxiety Disorder (GAD) Overview

Generalized Anxiety Disorder (GAD) is a prevalent mental health condition characterized by excessive and persistent worry, often extending beyond specific triggers. Individuals with GAD experience heightened levels of anxiety, anticipating future events and exhibiting physical symptoms such as muscle tension and restlessness. The disorder significantly impairs daily functioning and quality of life.

The pathophysiology of Generalized Anxiety Disorder (GAD) is associated with dysregulation in neurotransmitter systems, particularly involving imbalances in serotonin, gamma-aminobutyric acid (GABA), and norepinephrine. Structural and functional alterations in brain regions such as the amygdala, prefrontal cortex, and limbic system contribute to heightened reactivity to stressors, impaired emotional regulation, and the persistent, excessive worry characteristic of GAD.

Generalized Anxiety Disorder (GAD) Diagnosis

The diagnosis of Generalized Anxiety Disorder (GAD) involves a comprehensive assessment of an individual's mental health, considering the presence of excessive and uncontrollable worry across various aspects of life for a minimum of six months. Clinicians utilize standardized psychiatric interviews and validated screening tools to evaluate the severity of anxiety symptoms, along with a thorough exploration of associated physical and psychological manifestations. Differential diagnosis is crucial to rule out other psychiatric conditions, medical disorders, or substance-related issues that may mimic GAD symptoms. The diagnostic process also entails considering the impact of anxiety on daily functioning and its persistence in the absence of identifiable stressors. A multidimensional approach aids in ensuring an accurate diagnosis and facilitates the development of an effective treatment plan tailored to the individual's needs.

Generalized Anxiety Disorder (GAD) Treatment

The primary treatment goal for Generalized Anxiety Disorder (GAD) is to alleviate symptoms and improve overall functioning, aiming for a reduction in excessive and uncontrollable worry. Therapeutic interventions, including psychotherapy (such as cognitive-behavioral therapy) and pharmacotherapy (commonly with selective serotonin reuptake inhibitors or serotonin-norepinephrine reuptake inhibitors), are employed to achieve symptom relief, enhance coping mechanisms, and improve the individual's quality of life. Additionally, treatment strategies often focus on preventing relapse and managing coexisting conditions to support long-term well-being.

Generalized Anxiety Disorder (GAD) Epidemiology

As the market is derived using the patient-based model, the Generalized Anxiety Disorder (GAD) epidemiology chapter in the report provides historical as well as forecasted epidemiology segmented by Diagnosed Prevalent Cases of Generalized Anxiety Disorder (GAD), Gender-specific Diagnosed Prevalent cases of Generalized Anxiety Disorder (GAD), Age-specific Diagnosed Prevalent cases of Generalized Anxiety Disorder (GAD), and Severity-specific Diagnosed Prevalent cases of Generalized Anxiety Disorder (GAD) in the 7MM covering the United States, EU4 countries (Germany, France, Italy, and Spain) and the United Kingdom, and Japan, from 2019 to 2032. As per DelveInsight's estimations, the total diagnosed prevalent cases of Generalized Anxiety Disorder (GAD) in the 7MM was approximately 15,743,000 in 2022 and are projected to increase during the forecast period.

• The overall count of individuals diagnosed with Generalized Anxiety Disorder (GAD) in the United States was approximately 8,418,000 in 2022, and it is expected to increase at an estimated CAGR throughout the study period (2019-2023).
• Among EU4 and the UK, Germany had the highest diagnosed prevalent population of GAD, with 1,410,000 cases, followed by Italy and Spain in 2022. On the other hand, the UK had the lowest prevalent population in the European region in 2022.
• In 2022, Japan reported approximately 1,317,000 diagnosed prevalent cases of Generalized Anxiety Disorder (GAD), with expectations of a modest decline in these cases.
• Gender-specific diagnosed prevalent cases of Generalized Anxiety Disorder (GAD) showed that females were more affected by Generalized Anxiety Disorder (GAD) than males in the 7MM in 2022.
• As per DelveInsight's analysis, the diagnosed prevalent cases of GAD based on age were categorized into four groups: 18-29 years, 30-44 years, 45-59 years, and 60 years and above. The highest proportion of Generalized Anxiety Disorder (GAD) cases was estimated in the 45-59 years age group in the 7MM, while the least cases were in the age group 18-29 years.
• The cases of Generalized Anxiety Disorder (GAD) were classified based on severity levels, including mild, moderate, and severe. DelveInsight's estimations reveal that the highest number of severity-specific cases in the 7MM was attributed to moderate cases, totaling 6,811,000.

Generalized Anxiety Disorder (GAD) Drug Chapters

The drug chapter segment of the Generalized Anxiety Disorder (GAD) report encloses a detailed analysis of Generalized Anxiety Disorder (GAD) marketed drugs and mid-late stage (Phase III and Phase II) pipeline drugs. It also understands Generalized Anxiety Disorder (GAD) clinical trial details, expressive pharmacological action, agreements and collaborations, approval, and patent details, advantages and disadvantages of each included drug, and the latest news and press releases.

Emerging Drugs

Fasedienol (PH94B): VistaGen Therapeutics

PH94B presents a promising advancement in the GAD pipeline, characterized by its rapid onset, sustained therapeutic effect, and the convenience of a single administration. These attributes not only address the critical need for quicker relief in anxiety disorders but also enhance patient compliance. The unique profile of PH94B, combined with its potential to offer a durable response with minimal dosing, positions it as a valuable innovation in the treatment landscape for GAD. These factors underscores the compound's potential to redefine standards in anxiety disorder management, potentially providing a more efficient and patient-friendly alternative for individuals grappling with GAD.

MM-120 (LSD D-Tartrate): MindMed

MM-120 (LSD D-Tartrate) is under clinical development by MindMed, Inc. and is currently in Phase II for GAD treatment. Administered orally, it is a pharmacologically enhanced version of lysergic acid diethylamide (LSD). This candidate has promising and enduring benefits against symptoms of anxiety and depression.

Note: Detailed emerging therapies assessment will be provided in the final report of Generalized Anxiety Disorder (GAD).

Generalized Anxiety Disorder (GAD) Market Outlook

Generalized Anxiety Disorder (GAD) has a diverse treatment classification associated with the disease landscape. The standard array of pharmacological agents employed in the management of GAD encompasses a diverse range, including selective serotonin reuptake inhibitors (SSRIs), serotonin-norepinephrine reuptake inhibitors (SNRIs), antiepileptic's like pregabalin, tricyclic antidepressants (TCAs) that impact mood regulation, benzodiazepines offering rapid relief, antihistamines, atypical antipsychotics, and antioxidants.

The market for Generalized Anxiety Disorder (GAD) is expected to experience positive growth with the approval of potential drugs like Fasedienol, MM-120, and others.

• The Generalized Anxiety Disorder (GAD) market's total size in the 7MM reached approximately USD 1,500 million in 2022. Projections indicate a substantial growth during the forecast period.
• Out of the 7MM, the United States dominated the market in 2022, representing the largest share at nearly 64%.
• In 2022, EU4 and the UK captured an estimated USD 443 million, which is anticipated to increase at a substantial CAGR. Among the European countries, Germany covered the largest market share in 2022, followed by Italy, and Spain.
• Japan alone represented approximately 7% of the total Generalized Anxiety Disorder (GAD) market in 2022, projected to increase at a substantial CAGR during the study period.
• The total market size of the Generalized Anxiety Disorder (GAD) treatment market is anticipated to experience growth during the forecast period due to the emergence of new and effective treatments.

Generalized Anxiety Disorder (GAD) Drugs Uptake

This section focuses on the uptake rate of potential drugs expected to launch in the market during 2019-2032. For example, Fasedienol in the US is expected to be launch by 2027.

Further detailed analysis of emerging therapies drug uptake in the report…

Generalized Anxiety Disorder (GAD) Pipeline Development Activities

The report provides insights into different therapeutic candidates in Phase III, Phase II, and Phase I stage. It also analyzes key players involved in developing targeted therapeutics.

Pipeline Development Activities

The report covers information on collaborations, acquisitions and mergers, licensing, and patent details for Generalized Anxiety Disorder (GAD) emerging therapies.

KOL Views

To keep up with current market trends, we take KOLs and SMEs' opinions working in the domain through primary research to fill the data gaps and validate the secondary research. Industry Experts were contacted for insights on Generalized Anxiety Disorder (GAD) evolving treatment landscape, patient reliance on conventional therapies, patient therapy switching acceptability, and drug uptake along with challenges related to accessibility, including KOL from Department of Psychiatry and Behavioral Medicine, Louisiana State University Health Shreveport, LA; Clinical Mental Health Supervisor, Western Pennsylvania; Max-Planck-Institute of Psychiatry, Unit Clinical Psychology and Epidemiology, Germany; Department of Neuroscience and Imaging, University 'G. d'Annunzio', Chieti , Italy; National Center of Neurology and Psychiatry, Tokyo, Japan, and others.

DelveInsight's analysts connected with 50+ KOLs to gather insights; however, interviews were conducted with 15+ KOLs in the 7MM. Their opinion helps understand and validate current and emerging therapies, treatment patterns, or Generalized Anxiety Disorder (GAD) market trends. This will support the clients in potential upcoming novel treatments by identifying the overall scenario of the market and the unmet needs.

Qualitative Analysis

We perform Qualitative and market Intelligence analysis using various approaches, such as SWOT and Conjoint Analysis. In the SWOT analysis, strengths, weaknesses, opportunities, and threats in terms of disease diagnosis, patient awareness, patient burden, competitive landscape, cost-effectiveness, and geographical accessibility of therapies are provided. These pointers are based on the Analyst's discretion and assessment of the patient burden, cost analysis, and existing and evolving treatment landscape.

Conjoint Analysis analyzes multiple approved and emerging therapies based on relevant attributes such as safety, efficacy, frequency of administration, route of administration, and order of entry. Scoring is given based on these parameters to analyze the effectiveness of therapy.

Further, the therapies' safety is evaluated wherein the acceptability, tolerability, and adverse events are majorly observed, and it sets a clear understanding of the side effects posed by the drug in the trials. In addition, the scoring is also based on the route of administration, order of entry and designation, probability of success, and the addressable patient pool for each therapy. According to these parameters, the final weightage score and the ranking of the emerging therapies are decided.

Market Access and Reimbursement

The high cost of therapies for the treatment is a major factor restraining the growth of the global drug market. Because of the high cost, the economic burden is increasing, leading the patient to escape from proper treatment.

The report further provides detailed insights on the country-wise accessibility and reimbursement scenarios, cost-effectiveness scenario of approved therapies, programs making accessibility easier and out-of-pocket costs more affordable, insights on patients insured under federal or state government prescription drug programs, etc.

Scope of the Report:

• The report covers a segment of key events, an executive summary, descriptive overview of Generalized Anxiety Disorder (GAD), explaining its causes, signs and symptoms, pathogenesis, and currently available therapies.
• Comprehensive insight has been provided into the epidemiology segments and forecasts, the future growth potential of diagnosis rate, disease progression, and treatment guidelines.
• Additionally, an all-inclusive account of the current and emerging therapies and the elaborative profiles of late-stage and prominent therapies will impact the current treatment landscape.
• A detailed review of the Generalized Anxiety Disorder (GAD) market, historical and forecasted market size, market share by therapies, detailed assumptions, and rationale behind the approach is included in the report covering the 7MM drug outreach.
• The report provides an edge while developing business strategies, by understanding trends, through SWOT analysis and expert insights/KOL views, patient journey, and treatment preferences that help shape and drive the 7MM Generalized Anxiety Disorder (GAD) market.

Generalized Anxiety Disorder (GAD) Report Insights

• Patient Population
• Therapeutic Approaches
• Generalized Anxiety Disorder (GAD) Pipeline Analysis
• Generalized Anxiety Disorder (GAD) Market Size and Trends
• Existing and Future Market Opportunity

Generalized Anxiety Disorder (GAD) Report Key Strengths

• 10 years Forecast
• The 7MM Coverage
• Generalized Anxiety Disorder (GAD) Epidemiology Segmentation
• Key Cross Competition
• Conjoint Analysis
• Drugs Uptake and Key Market Forecast Assumptions

Generalized Anxiety Disorder (GAD) Report Assessment

• Current Treatment Practices
• Unmet Needs
• Pipeline Product Profiles
• Market Attractiveness
• Qualitative Analysis (SWOT and Conjoint Analysis)

Key Questions:

Market Insights

• What was the Generalized Anxiety Disorder (GAD) total market size, the market size by therapies, and market share (%) distribution in 2019, and how would it all look in 2032? What are the contributing factors for this growth?
• What unmet needs are associated with the current treatment market of Generalized Anxiety Disorder (GAD)?
• What are the patents of emerging therapies for Generalized Anxiety Disorder (GAD)?
• Which drug is going to be the largest contributor by 2032?
• What are the pricing variations among different geographies for approved and off-label therapies?
• How would the market drivers, barriers, and future opportunities affect the market dynamics and subsequent analysis of the associated trends?

Epidemiology Insights

• What are the disease risks, burdens, and unmet needs of Generalized Anxiety Disorder (GAD)? What will be the growth opportunities across the 7MM concerning the patient population of Generalized Anxiety Disorder (GAD)?
• What is the historical and forecasted Generalized Anxiety Disorder (GAD) patient pool in the United States, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan?
• Why do only limited patients appear for diagnosis?
• Which country is more prevalent for Generalized Anxiety Disorder (GAD) and why?
• What factors are affecting the diagnosis of the indication?

Current Treatment Scenario, Marketed Drugs, and Emerging Therapies

• What are the current options for treating Generalized Anxiety Disorder (GAD)? What are the current guidelines for treating Generalized Anxiety Disorder (GAD) in the US and Europe?
• How many companies are developing therapies for treating Generalized Anxiety Disorder (GAD)?
• How many emerging therapies are in the mid-stage and late stage of development for treating Generalized Anxiety Disorder (GAD)?
• What are the recent novel therapies, targets, mechanisms of action, and technologies developed to overcome the limitations of existing therapies?
• What are the key designations that have been granted for the emerging therapies for Generalized Anxiety Disorder (GAD)?
• Patient acceptability in terms of preferred treatment options as per real-world scenarios?
• What are the country-specific accessibility issues of expensive, recently approved therapies? Focus on reimbursement policies.
• What are the 7MM historical and forecasted markets of Generalized Anxiety Disorder (GAD)?

Reasons to Buy:

• The report will help develop business strategies by understanding the latest trends and changing treatment dynamics driving the Generalized Anxiety Disorder (GAD) Market.
• Insights on patient burden/disease prevalence, evolution in diagnosis, and factors contributing to the change in the epidemiology of the disease during the forecast years.
• To understand the existing market opportunity in varying geographies and the growth potential over the coming years.
• Distribution of historical and current patient share based on real-world prescription data along with reported sales of approved products in the US, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan.
• Identifying strong upcoming players in the market will help devise strategies that will help get ahead of competitors.
• Detailed analysis and ranking of potential current and emerging therapies under the conjoint analysis section to provide visibility around leading classes.
• Highlights of Access and Reimbursement policies of approved therapies, barriers to accessibility of off-label expensive therapies, and patient assistance programs.
• To understand the perspective of Key Opinion Leaders around the accessibility, acceptability, and compliance-related challenges of existing treatment to overcome barriers in the future.
• Detailed insights on the unmet needs of the existing market so that the upcoming players can strengthen their development and launch strategy.

Frequently Asked Questions

1. What is the forecast period covered in the report?

• The Generalized Anxiety Disorder (GAD) Epidemiology and Market Insight report for the 7MM covers the forecast period from 2023 to 2032, providing a projection of market dynamics and trends during this timeframe.

2. Who are the key players in the Generalized Anxiety Disorder (GAD) market?

• The Generalized Anxiety Disorder (GAD) market is very scare. The major players are VistaGen Therapeutics; MindMed, and others which are currently developing drugs for the treatment of Generalized Anxiety Disorder (GAD).

3. How is the market size estimated in the forecast report?

• The market size is estimated through data analysis, statistical modeling, and expert opinions. It may consider factors such as incident cases, treatment costs, revenue generated, and market trends.

4. What is the key driver of the Generalized Anxiety Disorder (GAD) market?

• The increase in diagnosed prevalent cases of Generalized Anxiety Disorder (GAD) and launch of emerging therapies are attributed to be the key drivers for increasing Generalized Anxiety Disorder (GAD) market.

5. What is the expected impact of emerging therapies or advancements in Generalized Anxiety Disorder (GAD) treatment on the market?

• Introducing new therapies, advancements in diagnostic techniques, and innovations in treatment approaches can significantly impact the Generalized Anxiety Disorder (GAD) treatment market. Market forecast reports may provide analysis and predictions regarding the potential impact of these developments.

6. Does the report provide insights into the competitive landscape of the market?

• The market forecast report may include information on the competitive landscape, profiling key market players, their product offerings, partnerships, and strategies, and helping stakeholders understand the competitive dynamics of the Generalized Anxiety Disorder (GAD) market.

Table of Contents

1. Key Insights

2. Report Introduction

3. Generalized Anxiety Disorder (GAD) Market Overview at a Glance

• 3.1. Market Share (%) Distribution by Therapies of GAD in 2019
• 3.2. Market Share (%) Distribution by Therapies of GAD in 2032

4. Epidemiology and Market Methodology of GAD

5. Executive Summary of Generalized Anxiety Disorder (GAD)

6. Key Events

7. Disease Background and Overview

• 7.1. Introduction
• 7.2. Causes and Risk Factors
• 7.3. Signs and Symptoms
• 7.4. Pathophysiology
• 7.5. Diagnosis
  • 7.5.1. Diagnostic Algorithm
  • 7.5.2. Screening Tools
• 7.6. Treatment and Management of Generalized Anxiety Disorder
  • 7.6.1. Treatment of special populations
  • 7.6.2. Treatment Algorithm
  • 7.6.3. Treatment Guidelines
    • 7.6.3.1. Recommendations as per American Family Physician
    • 7.6.3.2. National Institute for Health and Care Excellence (NICE): GAD Management
    • 7.6.3.3. Japanese Society of Anxiety and Related Disorders/Japanese Society of Neuropsychopharmacology: Clinical Practice Guideline for Social Anxiety Disorder (2021)
  • 7.6.4. Treatment Recommendation Summary

8. Epidemiology and Patient Population

• 8.1. Key Findings
• 8.2. Assumptions and Rationale of GAD
  • 8.2.1. The United States
  • 8.2.2. EU4 and the UK
  • 8.2.3. Japan
• 8.3. Total Diagnosed Prevalent Cases of GAD in the 7MM
• 8.4. The United States
  • 8.4.1. Total Diagnosed Prevalent Cases of GAD in the US
  • 8.4.2. Gender-specific Diagnosed Prevalent Cases of GAD in the US
  • 8.4.3. Age-specific Diagnosed Prevalent Cases of GAD in the US
  • 8.4.4. Severity-specific Diagnosed Prevalent Cases of GAD in the US
• 8.5. EU4 and the UK
  • 8.5.1. Germany
    • 8.5.1.1. Total Diagnosed Prevalent Cases of GAD in Germany
    • 8.5.1.2. Gender-specific Diagnosed Prevalent Cases of GAD in Germany
    • 8.5.1.3. Age-specific Diagnosed Prevalent Cases of GAD in Germany
    • 8.5.1.4. Severity-specific Diagnosed Prevalent Cases of GAD in Germany
  • 8.5.2. France
    • 8.5.2.1. Total Diagnosed Prevalent Cases of GAD in France
    • 8.5.2.2. Gender-specific Diagnosed Prevalent Cases of GAD in France
    • 8.5.2.3. Age-specific Diagnosed Prevalent Cases of GAD in France
    • 8.5.2.4. Severity-specific Diagnosed Prevalent Cases of GAD in France
  • 8.5.3. Italy
    • 8.5.3.1. Total Diagnosed Prevalent Cases of GAD in Italy
    • 8.5.3.2. Gender-specific Diagnosed Prevalent Cases of GAD in Italy
    • 8.5.3.3. Age-specific Diagnosed Prevalent Cases of GAD in Italy
    • 8.5.3.4. Severity-specific Diagnosed Prevalent Cases of GAD in Italy
  • 8.5.4. Spain
    • 8.5.4.1. Total Diagnosed Prevalent Cases of GAD in Spain
    • 8.5.4.2. Gender-specific Diagnosed Prevalent Cases of GAD in Spain
    • 8.5.4.3. Age-specific Diagnosed Prevalent Cases of GAD in Spain
    • 8.5.4.4. Severity-specific Diagnosed Prevalent Cases of GAD in Spain
  • 8.5.5. The UK
    • 8.5.5.1. Total Diagnosed Prevalent Cases of GAD in the UK
    • 8.5.5.2. Gender-specific Diagnosed Prevalent Cases of GAD in the UK
    • 8.5.5.3. Age-specific Diagnosed Prevalent Cases of GAD in the UK
    • 8.5.5.4. Severity-specific Diagnosed Prevalent Cases of GAD in the UK
• 8.6. Japan
  • 8.6.1. Total Diagnosed Prevalent Cases of GAD in Japan
  • 8.6.2. Gender-specific Diagnosed Prevalent Cases of GAD in Japan
  • 8.6.3. Age-specific Diagnosed Prevalent Cases of GAD in Japan
  • 8.6.4. Severity-specific Diagnosed Prevalent Cases of GAD in Japan

9. Patient Journey of GAD

10. Emerging Therapies

• 10.1. Key Cross Competition
• 10.2. Fasedienol (PH94B): VistaGen Therapeutics
  • 10.2.1. Product Description
  • 10.2.2. Other Development Activities
  • 10.2.3. Clinical development
  • 10.2.4. Clinical Trials Information
  • 10.2.5. Safety and Efficacy
  • 10.2.6. Product Profile
  • 10.2.7. Analysts' Views
• 10.3. MM-120: MindMed
  • 10.3.1. Product Description
  • 10.3.2. Other Developmental Activities
  • 10.3.3. Clinical development
  • 10.3.4. Clinical Trials Information
  • 10.3.5. Product Profile
  • 10.3.6. Analysts' Views
• 10.4. SEP-363856 (Ulotaront): Sumitomo Pharma America, Inc./Otsuka Pharmaceutical Co., Ltd/Sunovion Pharmaceuticals Inc.
  • 10.4.1. Product Description
  • 10.4.2. Other Development Activities
  • 10.4.3. Clinical Development
  • 10.4.4. Clinical Trials Information
  • 10.4.5. Product Profile
  • 10.4.6. Analysts' Views
• 10.5. CYB004: Cybin IRL Limited
  • 10.5.1. Product Description
  • 10.5.2. Other Development Activities
  • 10.5.3. Clinical Development
  • 10.5.4. Clinical Trials Information
  • 10.5.5. Product Profile
  • 10.5.6. Analysts' Views
• 10.6. ENX-102: Engrail Therapeutics INC
  • 10.6.1. Product Description
  • 10.6.2. Other Development Activities
  • 10.6.3. Clinical Development
  • 10.6.4. Clinical Trials Information
  • 10.6.5. Product Profile
  • 10.6.6. Analysts' Views
• 10.7. BNC210: Bionomics Limited
  • 10.7.1. Product Description
  • 10.7.2. Other Development Activities
  • 10.7.3. Clinical Development
  • 10.7.4. Clinical Trials Information
  • 10.7.5. Safety and Efficacy
  • 10.7.6. Product Profile
  • 10.7.7. Analysts' Views
• 10.8. RLS103: Receptor Life Sciences/MannKind Corporation
  • 10.8.1. Product Description
  • 10.8.2. Other Development Activities
  • 10.8.3. Clinical Development
  • 10.8.4. Clinical Trials Information
  • 10.8.5. Product Profile
  • 10.8.6. Analysts' Views

11. GAD: Market Analysis

• 11.1. Key Findings
• 11.2. Key Market Forecast Assumptions
• 11.3. Market Outlook
• 11.4. Total Market Size of GAD in the 7MM
• 11.5. Market Size of GAD by Therapies in the 7MM
• 11.6. Market Size of GAD in the United States
  • 11.6.1. Total Market Size of GAD
  • 11.6.2. Market Size of GAD by Therapies in the United States
• 11.7. Market Size of GAD in EU4 and the UK
  • 11.7.1. Germany
    • 11.7.1.1. Total Market Size of GAD
    • 11.7.1.2. Market Size of GAD by Therapies in Germany
  • 11.7.2. France
    • 11.7.2.1. Total Market Size of GAD
    • 11.7.2.2. Market Size of GAD by Therapies in France
  • 11.7.3. Italy
    • 11.7.3.1. Total Market Size of GAD
    • 11.7.3.2. Market Size of GAD by Therapies in Italy
  • 11.7.4. Spain
    • 11.7.4.1. Total Market Size of GAD
    • 11.7.4.2. Market Size of GAD by Therapies in Spain
  • 11.7.5. The UK
    • 11.7.5.1. Total Market Size of GAD
    • 11.7.5.2. Market Size of GAD by Therapies in the UK
• 11.8. Market Size of GAD in Japan
  • 11.8.1. Total Market Size of GAD
  • 11.8.2. Market Size of GAD by Therapies in Japan

12. Key Opinion Leaders' Views

13. SWOT Analysis

14. Unmet Needs

15. Market Access and Reimbursement

• 15.1. The United States
  • 15.1.1. Center for Medicare and Medicaid Services (CMS)
• 15.2. In EU4 and the UK
  • 15.2.1. Germany
  • 15.2.2. France
  • 15.2.3. Italy
  • 15.2.4. Spain
  • 15.2.5. The United Kingdom
• 15.3. Japan
  • 15.3.1. MHLW

16. Appendix

• 16.1. Bibliography
• 16.2. Acronyms and Abbreviations
• 16.3. Report Methodology

17. DelveInsight Capabilities

18. Disclaimer

관련자료